Pub Date : 2022-03-05DOI: 10.52711/2321-5836.2022.00001
D. Johnson, S. R., A. M, V. R.
Introduction: An inflammatory response appears after activation of immune response. Inflammation is a response to remove the primary cause of cell injury. Dead cells, damage tissue sand initiate the repair process. Inflammation may be of two types acute and chronic. Medicinal plants has a potential source of therapeutic aid has a attended a significant role in all over the world for both human and animals not only in the disease condition but also a potential for maintaining a proper health. The plant Bryophyllum pinnatum species (roots) are evaluated for anti-inflammatory activity. Aim: Anti-inflammatory activity of Bryophyllum pinnatum was evaluated using Carrageenan induced paw oedema, Histamine induced paw oedema and Egg white induced paw oedema. Materials and Methods: To prepare methanolic extracts of Bryophyllum pinnatum roots and investigate the anti-inflammatory activity by Carrageenan induced paw oedema, Histamine induced paw oedema and Egg white induced paw oedema. Result: The result obtained indicates that the extract found to have significant (p<0.0001) anti-inflammatory activity in rats. The extract at the test doses 200mg/kg reduced the oedema induced by carrageenan by 41.26% at 3 h, whereas the standard drug showed 47.35% of inhibition ass compared to the control group. Conclusion: The methanolic extract of Bryophyllum pinnatum are safe upto 500mg/kg for continues administration and it can be used as anti inflammatory agent without any harmful effects
{"title":"Anti-Inflammatory Activity Screening of Methanolic Extract of Bryophyllum pinnatum Root","authors":"D. Johnson, S. R., A. M, V. R.","doi":"10.52711/2321-5836.2022.00001","DOIUrl":"https://doi.org/10.52711/2321-5836.2022.00001","url":null,"abstract":"Introduction: An inflammatory response appears after activation of immune response. Inflammation is a response to remove the primary cause of cell injury. Dead cells, damage tissue sand initiate the repair process. Inflammation may be of two types acute and chronic. Medicinal plants has a potential source of therapeutic aid has a attended a significant role in all over the world for both human and animals not only in the disease condition but also a potential for maintaining a proper health. The plant Bryophyllum pinnatum species (roots) are evaluated for anti-inflammatory activity. Aim: Anti-inflammatory activity of Bryophyllum pinnatum was evaluated using Carrageenan induced paw oedema, Histamine induced paw oedema and Egg white induced paw oedema. Materials and Methods: To prepare methanolic extracts of Bryophyllum pinnatum roots and investigate the anti-inflammatory activity by Carrageenan induced paw oedema, Histamine induced paw oedema and Egg white induced paw oedema. Result: The result obtained indicates that the extract found to have significant (p<0.0001) anti-inflammatory activity in rats. The extract at the test doses 200mg/kg reduced the oedema induced by carrageenan by 41.26% at 3 h, whereas the standard drug showed 47.35% of inhibition ass compared to the control group. Conclusion: The methanolic extract of Bryophyllum pinnatum are safe upto 500mg/kg for continues administration and it can be used as anti inflammatory agent without any harmful effects","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87597824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-05DOI: 10.52711/2321-5836.2022.00006
Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, N. Jaiswal
Gene-based therapies for cancer in clinical trials include strategies that involve augmentation of immunotherapeutic and chemotherapeutic approaches. These strategies include ex vivo and in vivo cytokine gene transfer, drug sensitization with genes for prodrug delivery, and the use of drug-resistance genes for bone marrow protection from high-dose chemotherapy. Inactivation of oncogene expression and gene replacement for tumor suppressor genes are among the strategies for targeting the underlying genetic lesions in the cancer cell. A review of clinical trial results to date, primarily in patients with very advanced cancers refractory to conventional treatments, indicates that these treatments can mediate tumor regression with acceptably low toxicity. Vector development remains a critical area for future research. Important areas for future research include modifying viral vectors to reduce toxicity and immunogenicity, increasing the transduction efficiency of nonviral vectors, enhancing vector targeting and specificity, regulating gene expression, and identifying synergies between gene-based agents and other cancer therapeutics.
{"title":"Review on Gene Therapy on Cancer","authors":"Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tmabe, N. Jaiswal","doi":"10.52711/2321-5836.2022.00006","DOIUrl":"https://doi.org/10.52711/2321-5836.2022.00006","url":null,"abstract":"Gene-based therapies for cancer in clinical trials include strategies that involve augmentation of immunotherapeutic and chemotherapeutic approaches. These strategies include ex vivo and in vivo cytokine gene transfer, drug sensitization with genes for prodrug delivery, and the use of drug-resistance genes for bone marrow protection from high-dose chemotherapy. Inactivation of oncogene expression and gene replacement for tumor suppressor genes are among the strategies for targeting the underlying genetic lesions in the cancer cell. A review of clinical trial results to date, primarily in patients with very advanced cancers refractory to conventional treatments, indicates that these treatments can mediate tumor regression with acceptably low toxicity. Vector development remains a critical area for future research. Important areas for future research include modifying viral vectors to reduce toxicity and immunogenicity, increasing the transduction efficiency of nonviral vectors, enhancing vector targeting and specificity, regulating gene expression, and identifying synergies between gene-based agents and other cancer therapeutics.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83616425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-05DOI: 10.52711/2321-5836.2022.00008
Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tambe
Until recently, cancer therapy comprised of four main types of treatment: surgery, radiotherapy, chemotherapy and targeted therapy. Over the past decade, immuno-oncology (IO) has emerged as a novel and important approach to cancer treatment through the stimulation of the body’s own immune system to kill cancer cells. This newly recognised method of treating cancer is rapidly developing, with many accelerated approvals by the US Food and Drug Administration and European Medicines Agency in 2019. Several therapeutic classes have emerged within IO, and are the focus of this review article. In particular, the immune checkpoint inhibitors have had remarkable success across multiple malignancies, and are the most well-established therapeutic class of IO agents to date. Biomarker testing for the programmed death-ligand 1 (PD-L1) checkpoint target has been developed and is now obligatory before treatment with pembrolizumab (Keytruda, Merck) when used for non-small-cell lung carcinoma, gastric cancer, head and neck squamous cell carcinoma and cervical cancer, as well as before treatment with atezolizumab (Tecentriq, Roche) when used for urothelial carcinoma. However, ambiguity remains as to the relevance of PD-L1 expression for checkpoint inhibition therapy for other tumour types. More recently, combining IO agents with conventional therapies has been evaluated with some significant improvements in patient outcomes. While IO agents are rapidly changing the standard of care for people with cancer, there are still many challenges to overcome in terms of managing their toxicities and ensuring that healthcare systems, such as the NHS, can afford the high cost of these therapies. The IO pipeline also includes chimeric antigen receptor T-cell therapies and cancer vaccines, both of which show great promise for the future but have their own unique toxicity and cost-effectiveness issues.
{"title":"Review on Immuno-Oncology Agents for Cancer Therapy","authors":"Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tambe","doi":"10.52711/2321-5836.2022.00008","DOIUrl":"https://doi.org/10.52711/2321-5836.2022.00008","url":null,"abstract":"Until recently, cancer therapy comprised of four main types of treatment: surgery, radiotherapy, chemotherapy and targeted therapy. Over the past decade, immuno-oncology (IO) has emerged as a novel and important approach to cancer treatment through the stimulation of the body’s own immune system to kill cancer cells. This newly recognised method of treating cancer is rapidly developing, with many accelerated approvals by the US Food and Drug Administration and European Medicines Agency in 2019. Several therapeutic classes have emerged within IO, and are the focus of this review article. In particular, the immune checkpoint inhibitors have had remarkable success across multiple malignancies, and are the most well-established therapeutic class of IO agents to date. Biomarker testing for the programmed death-ligand 1 (PD-L1) checkpoint target has been developed and is now obligatory before treatment with pembrolizumab (Keytruda, Merck) when used for non-small-cell lung carcinoma, gastric cancer, head and neck squamous cell carcinoma and cervical cancer, as well as before treatment with atezolizumab (Tecentriq, Roche) when used for urothelial carcinoma. However, ambiguity remains as to the relevance of PD-L1 expression for checkpoint inhibition therapy for other tumour types. More recently, combining IO agents with conventional therapies has been evaluated with some significant improvements in patient outcomes. While IO agents are rapidly changing the standard of care for people with cancer, there are still many challenges to overcome in terms of managing their toxicities and ensuring that healthcare systems, such as the NHS, can afford the high cost of these therapies. The IO pipeline also includes chimeric antigen receptor T-cell therapies and cancer vaccines, both of which show great promise for the future but have their own unique toxicity and cost-effectiveness issues.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"120 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79363423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-21DOI: 10.52711/2321-5836.2021.00028
Sangita P. Shirsat, Kaveri P. Tambe, Ganesh G. Dhakad, P. Patil, Ritik. S. Jain
There are so many type of daisies are founded because of ‘Fungal’ such daisies given in follow. also the treatment on this particular daisies with the help of ‘Anti-fungal’ drug or anti- fungal agent and anti-fungal medication as follows The four main classes of antifungal drugs are the polyenes, Azoles, allylamines and echinocandins. Clinically useful “older” agents include topical azole Formulations (for superficial yeast and dermatophyte Infections), first-generation triazoles (fluconazole and Itraconazole, for a range of superficial and invasive fungal Infections), amphotericin B formulations (for a broad range of Invasive fungal infections) and terbinafine (for dermatophyte Infections). Clinically important “newer” agents include members of the Echinocandin class (eg, caspofungin) and second-generation Triazoles (eg, voriconazole and posaconazole). Voriconazole and posaconazole have broad-spectrum activity Against yeasts and moulds, including Aspergillus species. Posaconazole is the only azole drug with activity against Zygomycete fungi. Caspofungin and the other echinocandins are effective in Treating Candida and Aspergillus infections. The azoles are relatively safe, but clinicians should be aware of drug–drug interactions and adverse effects, including Visual disturbances (with voriconazole), elevations in liver Transaminase levels, and skin rashes. Caspofungin has Minimal adverse effects. Combination antifungal therapy may be appropriate in Selected patients with invasive fungal infections, but is Empiric and driven by individual physician practice. Clinical needs for novel antifungal agents have altered
{"title":"Review on Antifungal Agents","authors":"Sangita P. Shirsat, Kaveri P. Tambe, Ganesh G. Dhakad, P. Patil, Ritik. S. Jain","doi":"10.52711/2321-5836.2021.00028","DOIUrl":"https://doi.org/10.52711/2321-5836.2021.00028","url":null,"abstract":"There are so many type of daisies are founded because of ‘Fungal’ such daisies given in follow. also the treatment on this particular daisies with the help of ‘Anti-fungal’ drug or anti- fungal agent and anti-fungal medication as follows The four main classes of antifungal drugs are the polyenes, Azoles, allylamines and echinocandins. Clinically useful “older” agents include topical azole Formulations (for superficial yeast and dermatophyte Infections), first-generation triazoles (fluconazole and Itraconazole, for a range of superficial and invasive fungal Infections), amphotericin B formulations (for a broad range of Invasive fungal infections) and terbinafine (for dermatophyte Infections). Clinically important “newer” agents include members of the Echinocandin class (eg, caspofungin) and second-generation Triazoles (eg, voriconazole and posaconazole). Voriconazole and posaconazole have broad-spectrum activity Against yeasts and moulds, including Aspergillus species. Posaconazole is the only azole drug with activity against Zygomycete fungi. Caspofungin and the other echinocandins are effective in Treating Candida and Aspergillus infections. The azoles are relatively safe, but clinicians should be aware of drug–drug interactions and adverse effects, including Visual disturbances (with voriconazole), elevations in liver Transaminase levels, and skin rashes. Caspofungin has Minimal adverse effects. Combination antifungal therapy may be appropriate in Selected patients with invasive fungal infections, but is Empiric and driven by individual physician practice. Clinical needs for novel antifungal agents have altered","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"156 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75297425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-21DOI: 10.52711/2321-5836.2021.00029
Ravi Kumar, Atul Rana
Sterilization, which is any process, physical or chemical, that destroys all forms of life, it is used especially to destroy microorganisms, spores, and viruses. Precisely defined, sterilization is the complete destruction of all microorganisms by a suitable chemical agent or by heat, either wet steam. In this review, we discussed about various suitable techniques that used for removing of infectious agents. The heat sterilization can be applied only to the thermostable products, and chemical sterilization is also used for any types of plastic or glass materials that degrade with heat. The Gas sterilization involves exposing equipment to chemical gases in an enclosed heated or pressurized chamber.
{"title":"Basic Concepts of Sterilization Techniques","authors":"Ravi Kumar, Atul Rana","doi":"10.52711/2321-5836.2021.00029","DOIUrl":"https://doi.org/10.52711/2321-5836.2021.00029","url":null,"abstract":"Sterilization, which is any process, physical or chemical, that destroys all forms of life, it is used especially to destroy microorganisms, spores, and viruses. Precisely defined, sterilization is the complete destruction of all microorganisms by a suitable chemical agent or by heat, either wet steam. In this review, we discussed about various suitable techniques that used for removing of infectious agents. The heat sterilization can be applied only to the thermostable products, and chemical sterilization is also used for any types of plastic or glass materials that degrade with heat. The Gas sterilization involves exposing equipment to chemical gases in an enclosed heated or pressurized chamber.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"80 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80028098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-21DOI: 10.52711/2321-5836.2021.00023
Sharad Desai, Nilesh Patel
Participation of humans in clinical research is always remained questionable. Hence evaluation of such doubt helps to conclude the perception about such participation. This research presents the process for development and validation of questionnaire for Healthy Adult Human Participants of Early Phase Bioequivalence Pharmacokinetic Endpoint Study. For development of questionnaire, literature search, experts’ discussion and authors’ experience was used for domain identification and its segregation for different variables. For validity of questionnaire, face validity and content validity was performed. Modification was done based on response from experts during non-quantitative face validity. % of overall agreement was 94.55 for question asked in face validity. While, Content Validity Ratio and Content Validity Index was calculated using the process mentioned by Lawshe and Lynn respectively. Initially 83 items were identified but based on validation 84 items were finalized after removal of three and addition of four questions. Deleted three items had Content Validity Ratio of 0.00, 0.67 and 0.67 and which were below accepted level of 0.99. While, I-CVI was observed from range of 0.83 to 1.00 and S-CVI values were above acceptable level of 0.90 for S-CVI (S-CVI/ Ave) and 0.80 for S-CVI (S-CVI/UA) for whole questionnaire and each part.
{"title":"Development and Validity of Questionnaire for Healthy Adult Human Participants of Early Phase Bioequivalence Pharmacokinetic Endpoint Study","authors":"Sharad Desai, Nilesh Patel","doi":"10.52711/2321-5836.2021.00023","DOIUrl":"https://doi.org/10.52711/2321-5836.2021.00023","url":null,"abstract":"Participation of humans in clinical research is always remained questionable. Hence evaluation of such doubt helps to conclude the perception about such participation. This research presents the process for development and validation of questionnaire for Healthy Adult Human Participants of Early Phase Bioequivalence Pharmacokinetic Endpoint Study. For development of questionnaire, literature search, experts’ discussion and authors’ experience was used for domain identification and its segregation for different variables. For validity of questionnaire, face validity and content validity was performed. Modification was done based on response from experts during non-quantitative face validity. % of overall agreement was 94.55 for question asked in face validity. While, Content Validity Ratio and Content Validity Index was calculated using the process mentioned by Lawshe and Lynn respectively. Initially 83 items were identified but based on validation 84 items were finalized after removal of three and addition of four questions. Deleted three items had Content Validity Ratio of 0.00, 0.67 and 0.67 and which were below accepted level of 0.99. While, I-CVI was observed from range of 0.83 to 1.00 and S-CVI values were above acceptable level of 0.90 for S-CVI (S-CVI/ Ave) and 0.80 for S-CVI (S-CVI/UA) for whole questionnaire and each part.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"161 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84679018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-21DOI: 10.52711/2321-5836.2021.00026
Sharad Desai, Nilesh Patel
Nowadays health agencies of regulated markets are becoming stringent regarding the bio-studies. So clinical/contract research organization (CRO) need to be selected carefully after their detailed assessment. As per requirement of bio-study CRO should be assessed with the study specific checklist of questions before awarding the bio-study. Questions related to various services of study like: Clinic phase, analytical phase, Pharmacokinetic and statistical phase, ethics approval, QA/QC, record handing etc. and related to CRO capabilities are discussed here with their relevance to conclude the abilities of CRO for successful execution of bio-study. Hence, this paper focuses all possible questions which need to be assessed before selection of CRO mainly for Bioavailability/Bioequivalence (BABE) study in healthy adult volunteers. Properly selected CRO will help for smooth execution of study and quality report and subsequently, hassle-free approval of dossier submitted to regulatory agency.
{"title":"Checklist to select contract Research Organization for early phase Bioavailability/Bioequivalence Clinical Studies in Healthy Adult Human Volunteers","authors":"Sharad Desai, Nilesh Patel","doi":"10.52711/2321-5836.2021.00026","DOIUrl":"https://doi.org/10.52711/2321-5836.2021.00026","url":null,"abstract":"Nowadays health agencies of regulated markets are becoming stringent regarding the bio-studies. So clinical/contract research organization (CRO) need to be selected carefully after their detailed assessment. As per requirement of bio-study CRO should be assessed with the study specific checklist of questions before awarding the bio-study. Questions related to various services of study like: Clinic phase, analytical phase, Pharmacokinetic and statistical phase, ethics approval, QA/QC, record handing etc. and related to CRO capabilities are discussed here with their relevance to conclude the abilities of CRO for successful execution of bio-study. Hence, this paper focuses all possible questions which need to be assessed before selection of CRO mainly for Bioavailability/Bioequivalence (BABE) study in healthy adult volunteers. Properly selected CRO will help for smooth execution of study and quality report and subsequently, hassle-free approval of dossier submitted to regulatory agency.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72702618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-21DOI: 10.52711/2321-5836.2021.00024
S. Sweta, Navdeep Singh
With the development and spread of 2019 novel coronavirus (2019-nCoV), also known as the severe acute respiratory syndrome coronavirus 2, a new public health disaster is threatening the world (SARS-CoV-2). In December 2019, the virus was discovered in bats and transmitted to humans via unidentified intermediary species in Wuhan, Hubei Province, China. To date (05/03/2020), there have been roughly 96,000 recorded cases of coronavirus disease 2019 (COVID-2019) and 3300 documented deaths. The disease is spread through inhalation or contact with contaminated droplets, with a 2 to 14-day incubation period. Fever, cough, sore throat, dyspnea, weariness, and malaise are common symptoms. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it can lead to pneumonia, ARDS (acute respiratory distress syndrome), and multi-organ failure. A large number of persons are asymptomatic. The case fatality rate is expected to be between 2 and 3%. Specimen collection, assay collection, serology, nucleic acid testing or molecular testing, and target selection for RT-PCR are all examples of laboratory diagnosis. Home isolation of suspected cases and those with mild illnesses, as well as tight infection control measures in hospitals, including contact and droplet precautions, are all part of the prevention strategy. The virus has a lower fatality rate than its two ancestors, SARS-CoV and Middle East respiratory sickness coronavirus (MERS-CoV). The global consequences of this new epidemic are still unknown.
{"title":"A Decisive Review to Understand the Basic Fundamentals of Novel Corona Viruse Disease","authors":"S. Sweta, Navdeep Singh","doi":"10.52711/2321-5836.2021.00024","DOIUrl":"https://doi.org/10.52711/2321-5836.2021.00024","url":null,"abstract":"With the development and spread of 2019 novel coronavirus (2019-nCoV), also known as the severe acute respiratory syndrome coronavirus 2, a new public health disaster is threatening the world (SARS-CoV-2). In December 2019, the virus was discovered in bats and transmitted to humans via unidentified intermediary species in Wuhan, Hubei Province, China. To date (05/03/2020), there have been roughly 96,000 recorded cases of coronavirus disease 2019 (COVID-2019) and 3300 documented deaths. The disease is spread through inhalation or contact with contaminated droplets, with a 2 to 14-day incubation period. Fever, cough, sore throat, dyspnea, weariness, and malaise are common symptoms. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it can lead to pneumonia, ARDS (acute respiratory distress syndrome), and multi-organ failure. A large number of persons are asymptomatic. The case fatality rate is expected to be between 2 and 3%. Specimen collection, assay collection, serology, nucleic acid testing or molecular testing, and target selection for RT-PCR are all examples of laboratory diagnosis. Home isolation of suspected cases and those with mild illnesses, as well as tight infection control measures in hospitals, including contact and droplet precautions, are all part of the prevention strategy. The virus has a lower fatality rate than its two ancestors, SARS-CoV and Middle East respiratory sickness coronavirus (MERS-CoV). The global consequences of this new epidemic are still unknown.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84615958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-21DOI: 10.52711/2321-5836.2021.00033
Sharad Desai, Nilesh Patel
This paper presents the results of Demographic and Participation Details of Healthy Adult Human Participants of Early Phase Bioequivalence Pharmacokinetic Endpoint Study. For that data of 50 participants was collected using self-administered questionnaire. After ethics approval, data were collected between between Jul-21 and Aug-21 from Gujarat state of India. Results of demographic and participation details are tabulated by its frequency and percentage. Participants are participating more whose age range were 18-41 years, income less than one lakh, education below Higher Secondary and having private job or wage-earner. Age of first time participation was found in range of 18-41 years and frequency of number studies in which participant participated were found from 01 to 20 studies. Also Chi-Square results suggested there is significant (p < 0.05) relation (I) between the Education and Age of first time participation (II) between the occupation and number of times participated.
{"title":"Demographic and Participation Details of Healthy Adult Human Participants of Early Phase Bioequivalence Pharmacokinetic Endpoint Study","authors":"Sharad Desai, Nilesh Patel","doi":"10.52711/2321-5836.2021.00033","DOIUrl":"https://doi.org/10.52711/2321-5836.2021.00033","url":null,"abstract":"This paper presents the results of Demographic and Participation Details of Healthy Adult Human Participants of Early Phase Bioequivalence Pharmacokinetic Endpoint Study. For that data of 50 participants was collected using self-administered questionnaire. After ethics approval, data were collected between between Jul-21 and Aug-21 from Gujarat state of India. Results of demographic and participation details are tabulated by its frequency and percentage. Participants are participating more whose age range were 18-41 years, income less than one lakh, education below Higher Secondary and having private job or wage-earner. Age of first time participation was found in range of 18-41 years and frequency of number studies in which participant participated were found from 01 to 20 studies. Also Chi-Square results suggested there is significant (p < 0.05) relation (I) between the Education and Age of first time participation (II) between the occupation and number of times participated.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83839586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-12-21DOI: 10.52711/2321-5836.2021.00031
V. N. Kumar Babu, N. Khurana
Parkinson’s disease (PD) is the common physical movement disorder, and it is 2nd most progressive widespread neurodegenerative disorder all over the world, and it is reported that and essential 10 million, over 0.3 % of the total world population. A thoughtful reduction of the neurotransmitter dopamine (DA) in the striatum is the main cause of these motor symptoms, collectively known as parkinsonism. Mitochondria serves as most important organelle in most of the cells and are essential for life and it is also called as heart for all cellular metabolisms. The main and most important role of mitochondria is generation of ATP via oxidative phosphorylation. In this study will study about how complex Ⅰ deficiency effects the mitochondrial and oxidative stress and reactive oxygen species which cause mitochondrial dysfunction and we also study emerging therapies for Parkinson disease with the help of coenzyme Q10 and some genes like FUN-14, FUNDC-1 and dimethyl fumarate or BG-12 in some phases of clinical trials and also by cell transplantation therapy and in future this study helps in finding how this sporadic Parkinson disease occurs in parkinsonism.
{"title":"A Review on Mitochondrial Dysfunction and Oxidative stress due to Complex-Ⅰ in Parkinson Disease","authors":"V. N. Kumar Babu, N. Khurana","doi":"10.52711/2321-5836.2021.00031","DOIUrl":"https://doi.org/10.52711/2321-5836.2021.00031","url":null,"abstract":"Parkinson’s disease (PD) is the common physical movement disorder, and it is 2nd most progressive widespread neurodegenerative disorder all over the world, and it is reported that and essential 10 million, over 0.3 % of the total world population. A thoughtful reduction of the neurotransmitter dopamine (DA) in the striatum is the main cause of these motor symptoms, collectively known as parkinsonism. Mitochondria serves as most important organelle in most of the cells and are essential for life and it is also called as heart for all cellular metabolisms. The main and most important role of mitochondria is generation of ATP via oxidative phosphorylation. In this study will study about how complex Ⅰ deficiency effects the mitochondrial and oxidative stress and reactive oxygen species which cause mitochondrial dysfunction and we also study emerging therapies for Parkinson disease with the help of coenzyme Q10 and some genes like FUN-14, FUNDC-1 and dimethyl fumarate or BG-12 in some phases of clinical trials and also by cell transplantation therapy and in future this study helps in finding how this sporadic Parkinson disease occurs in parkinsonism.","PeriodicalId":20945,"journal":{"name":"Research Journal of Pharmacology and Pharmacodynamics","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80505908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：